Dyne Therapeutics, Inc. Common Stock (DYN) is a publicly traded Healthcare sector company. As of May 20, 2026, DYN trades at $16.57 with a market cap of $2.73B and a P/E ratio of -4.65. DYN moved +4.59% today. Year to date, DYN is -13.95%; over the trailing twelve months it is +36.54%. Its 52-week range spans $6.36 to $36.09. Analyst consensus is strong buy with an average price target of $35.31. Rallies surfaces DYN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
DYN financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. DYN recently traded at $16.57. Market cap is $2.73B. P/E ratio is -4.65. Revenue is $0.
| Metric | Value |
|---|---|
| Price | $16.57 |
| Market Cap | $2.73B |
| P/E Ratio | -4.65 |
| EPS | $-3.47 |
| Dividend Yield | 0.00% |
| 52-Week High | $36.09 |
| 52-Week Low | $6.36 |
| Volume | 362.68K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-446.21M |
| Gross Margin | 0.00% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0 | $-446.21M | $-3.47 |
| 2024 | $0 | $-317.42M | $-3.37 |
| 2023 | $0 | $-235.94M | $-3.95 |
| 2022 | $0 | $-168.10M | $-3.23 |
11 analysts cover DYN: 0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.31.